Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 17Neoplasms 14Breast Neoplasms 11Melanoma 10Lung Neoplasms 9Multiple Myeloma 8Colorectal Neoplasms 8Prostatic Neoplasms 7Neoplasm Metastasis 7Leukemia, Myeloid, Acute 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hodgkin Disease 5Brain Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Rectal Neoplasms 4Myelodysplastic Syndromes 4Hematologic Neoplasms 4Glioblastoma 4Endometrial Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma 3

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1DEAE-Dextran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Oligoprogressive × 30 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡